Value Sense
RGEN
Repligen Corporation (RGEN)
Last Price$155.4(2.4%)
Market Cap$8,979.7M
Intrinsic value score
6/10
Good
Intrinsic value
$29.8
DCF value - $1.1 Relative value - $58.5
Overvalued
80.8%
LTM P/E
(433.2x)
Peer set median 31.0x
Discount rate
8.0%
RGEN
is 80.8% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

RGEN Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 RGEN Relative Value is $60.4, which is overvalued by 61.1%, compared to current share price of $155.4.
DCF Value vs Current Share Price
As of Mar 03, 2025 RGEN DCF Value is $1.1, which is overvalued by 99.3%, compared to current share price of $155.4.
Methodology
Price per share, $
RGEN
Intrinsic value$29.8
Overvalued by80.8%
Current share price
155.4
Relative value
60.4
DCF value
1.1

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

RGEN Historical Intrinsic Value

Crunching data... Almost there!

RGEN vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Repligen Corporation logo
Repligen CorporationRGEN
(80.8%)
(21.1%)
(80.9%)
5.6%
Median Peer Set
3.4%
23.0%
10.4%
Intuitive Surgical, Inc. logo
Intuitive Surgical, Inc.ISRG
(81.3%)
17.2%
27.7%
27.8%
West Pharmaceutical Services, Inc. logo
West Pharmaceutical Services, Inc.WST
(33.0%)
(1.9%)
(15.5%)
17.0%
Masimo Corporation logo
Masimo CorporationMASI
(26.6%)
0.6%
(42.5%)
4.0%
ResMed Inc. logo
ResMed Inc.RMD
(18.2%)
10.9%
13.4%
21.8%
Alcon Inc. logo
Alcon Inc.ALC
(13.6%)
8.5%
182.9%
10.3%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
1.2%
8.4%
32.2%
10.1%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
15.0%
4.2%
18.3%
8.4%
AptarGroup, Inc. logo
AptarGroup, Inc.ATR
19.0%
2.7%
30.2%
10.5%
Baxter International Inc. logo
Baxter International Inc.BAX
51.1%
(69.5%)
(100.0%)
(6.9%)
Hologic, Inc. logo
Hologic, Inc.HOLX
108.2%
(0.0%)
81.1%
19.6%

Explore more intrinsic value tools hub for RGEN

DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate

FAQ

What is Repligen Corporation intrinsic value?

As of Mar 03, 2025, Repligen Corporation Intrinsic Value is $29.8. This suggests it may be overvalued by 80.8% compared to its current price of around $155.4.

What is Repligen Corporation DCF (discounted cash flow) valuation?

As of Mar 03, 2025, Repligen Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $1.1. This suggests it may be overvalued by 99.3% to its current price of around $155.4, using a discount rate of 8.0% and terminal growth rate of 3.0%.

Is Repligen Corporation overvalued or undervalued?

Repligen Corporation is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $29.8, compared to a market price of around $155.4. This suggests a potential overvaluation of 80.8%.